MR 001
Alternative Names: MR-001Latest Information Update: 19 Dec 2023
At a glance
- Originator Vacino Biotech
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer; Lung cancer
Most Recent Events
- 19 Dec 2023 Discontinued for Breast cancer in China (Parenteral) (Vacino Biotech pipeline, December 2023)
- 19 Dec 2023 Discontinued for Lung cancer in China (Parenteral) (Vacino Biotech pipeline, December 2023)
- 18 Nov 2023 Nanfang Hospital, Southern Medical University plans a phase I trial for Solid tumors (Late-staged disease, Metastatic disease, Second line therapy or greater) in China (IV), in November 2023 (NCT06134531)